{"id":"ramipril-and-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the conversion of angiotensin I to angiotensin II, ramipril reduces blood pressure and decreases the workload on the heart. Hydrochlorothiazide works by increasing the amount of urine produced by the kidneys, which helps to lower blood pressure and reduce fluid buildup in the body.","oneSentence":"Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, while hydrochlorothiazide is a thiazide diuretic that increases urine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:20.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Chronic heart failure"}]},"trialDetails":[{"nctId":"NCT05963568","phase":"PHASE3","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2026-01-01","conditions":"Stroke, Medication Adherence","enrollment":680},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT05685277","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-12-28","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00574834","phase":"EARLY_PHASE1","title":"Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":17},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT01302899","phase":"PHASE2","title":"To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Non-diabetic Nephropathy","enrollment":8},{"nctId":"NCT00355589","phase":"PHASE3","title":"Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Hypertension, Blood Pressure, High","enrollment":""},{"nctId":"NCT00368277","phase":"PHASE3","title":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Hypertension","enrollment":901},{"nctId":"NCT00772577","phase":"PHASE4","title":"Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Hypertension","enrollment":386},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":"Hypertension, Type 2 Diabetes","enrollment":440}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":2,"reaction":"ACIDOSIS"},{"count":2,"reaction":"ACUTE PULMONARY OEDEMA"},{"count":2,"reaction":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS"},{"count":2,"reaction":"IDIOSYNCRATIC DRUG REACTION"},{"count":2,"reaction":"LEUKOPENIA"},{"count":1,"reaction":"APHASIA"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CNS VENTRICULITIS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ramipril and hydrochlorothiazide","genericName":"Ramipril and hydrochlorothiazide","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, while hydrochlorothiazide is a thiazide diuretic that increases urine production. Used for Hypertension, Chronic heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}